Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Heron Therapeutics (HRTX) over the last 13 years, with Dec 2024 value amounting to $25.8 million.

  • Heron Therapeutics' Cash & Equivalents rose 67.31% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.1 million, marking a year-over-year increase of 67.31%. This contributed to the annual value of $25.8 million for FY2024, which is 10.03% down from last year.
  • Per Heron Therapeutics' latest filing, its Cash & Equivalents stood at $25.8 million for FY2024, which was down 10.03% from $28.7 million recorded in FY2023.
  • Heron Therapeutics' Cash & Equivalents' 5-year high stood at $105.1 million during FY2020, with a 5-year trough of $15.4 million in FY2022.
  • Over the past 3 years, Heron Therapeutics' median Cash & Equivalents value was $25.8 million (recorded in 2024), while the average stood at $23.3 million.
  • In the last 5 years, Heron Therapeutics' Cash & Equivalents slumped by 83.03% in 2022 and then surged by 86.65% in 2023.
  • Over the past 5 years, Heron Therapeutics' Cash & Equivalents (Yearly) stood at $105.1 million in 2020, then declined by 13.88% to $90.5 million in 2021, then tumbled by 83.03% to $15.4 million in 2022, then surged by 86.65% to $28.7 million in 2023, then dropped by 10.03% to $25.8 million in 2024.